RECRUITING

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.

Official Title

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

Quick Facts

Study Start:2023-08-23

Study Completion:2027-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06549413

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* \* ≥ 18 years of age * Patients with locally advanced esophageal cancer * Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy * Ability to provide written informed consent in accordance with institutional policies * Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical	* \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed * Pregnant or lactating females * Have an allergy to intravenous contrast * eGFR \< 30

Inclusion Criteria

Exclusion Criteria

* \* ≥ 18 years of age
* Patients with locally advanced esophageal cancer
* Patients with untreated documented carcinoma of the esophagus that is \> 2 cm who are going to receive systemic therapy concurrently with radiation as primary therapy
* Ability to provide written informed consent in accordance with institutional policies
* Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 1 week of the proposed investigational PET/CT scan(s) prior to injection of the investigational radiopharmaceutical

* \* Body weight ≥ 400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
* Pregnant or lactating females
* Have an allergy to intravenous contrast
* eGFR \< 30

Contacts and Locations

Study Contact

Steven H Lin, MD, PHD

CONTACT

713-563-2300

shlin@mdanderson.org

Principal Investigator

Steven H Lin, MD, PHD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Steven H Lin, MD, PHD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-23

Study Completion Date2027-12-31

Study Record Updates

Study Start Date2023-08-23

Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

Esophageal Carcinoma